Page 7 - எங்களுக்கு ஆரோக்கியம் வளங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Advertisement 340B Drug Pricing Discount Program Update: HRSA Now Demands That Drug Manufacturers Provide 340B Discounts To Contract Pharmacies Amid Ongoing Litigation Friday, July 2, 2021 Now approaching a year-long battle, drug manufacturers and 340B covered entities, which includes hospitals and community health centers, participating in the 340B Drug Pricing Discount Program (“340B Participants”) continue to dispute the issue of whether drug manufacturers are required to give 340B Participants discounts on drugs dispensed through contract pharmacies.  The most recent point of contention involves the U.S. Health Resources and Services Administration’s (“HRSA”) May 17, 2021 letters sent to six drug manufacturers stating that the manufacturers’ actions to limit access to 340B Program pricing for 340B Participants who dispense drugs through contract pharmacies is in direct violation of Section 340B of the Public Health Service Act (also referred to as the

Eli lillyUs health resourcesUs department of healthAmerican hospital associationB program litigationB programHealthcare foundationPublic health serviceB drug pricing discount programServices administrationHuman serviceDrug pricing discount programPublic health service actProgram litigationAdvisory opinionCivil monetary penalties final rule